丁酰胆碱酯酶K变体和载脂蛋白E4基因在芬兰晚发性阿尔茨海默病患者中不存在协同作用。
Butyrylcholinesterase K variant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer's disease patients.
作者信息
Hiltunen M, Mannermaa A, Helisalmi S, Koivisto A, Lehtovirta M, Ryynänen M, Riekkinen P, Soininen H
机构信息
Department of Neurology, University Hospital and University of Kuopio, Finland.
出版信息
Neurosci Lett. 1998 Jun 26;250(1):69-71. doi: 10.1016/s0304-3940(98)00453-4.
Examination of the allelic frequency of the butyrylcholinesterase K (BChE-K) variant gene revealed no increase among Finnish late-onset Alzheimer's disease (AD) patients either as a whole or among a subset of AD patients carrying the epsilon4 allele of apolipoprotein E (ApoE4). In contrast, BChE-K allele frequency was significantly reduced in the Finnish AD patient group under 75 years of age carrying the ApoE4 allele when compared to the non-demented controls (chi2, P < 0.05). The proportion of subjects with both BChE-K and ApoE4 alleles was 14% and 41% in AD and control groups, respectively (chi2, P < 0.01; odds-ratio 0.22, 95% CI 0.07-0.71). These results are in contrast to a previous study on English AD patients, in which the genes for BChE-K and ApoE4 were suggested to act in synergy.
对丁酰胆碱酯酶K（BChE-K）变异基因的等位基因频率检测显示，在芬兰晚发性阿尔茨海默病（AD）患者群体中，无论是整体还是携带载脂蛋白E（ApoE4）ε4等位基因的AD患者亚组，该基因频率均未升高。相反，与非痴呆对照组相比，在芬兰75岁以下携带ApoE4等位基因的AD患者组中，BChE-K等位基因频率显著降低（卡方检验，P < 0.05）。AD组和对照组中同时携带BChE-K和ApoE4等位基因的受试者比例分别为14%和41%（卡方检验，P < 0.01；优势比0.22，95%可信区间0.07 - 0.71）。这些结果与之前一项针对英国AD患者的研究相反，在该研究中，BChE-K和ApoE4基因被认为具有协同作用。
Zotero 插件